13.08
price up icon3.15%   0.40
pre-market  Pre-market:  13.20   0.12   +0.92%
loading
Arcutis Biotherapeutics Inc stock is traded at $13.08, with a volume of 1.45M. It is up +3.15% in the last 24 hours and down -12.74% over the past month. Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$12.68
Open:
$12.78
24h Volume:
1.45M
Relative Volume:
0.72
Market Cap:
$1.53B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.3367
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-1.51%
1M Performance:
-12.74%
6M Performance:
+34.15%
1Y Performance:
+302.46%
1-Day Range:
Value
$12.78
$13.37
1-Week Range:
Value
$12.61
$14.36
52-Week Range:
Value
$3.295
$16.20

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
Name
Arcutis Biotherapeutics Inc
Name
Phone
805-418-5006
Name
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
Employee
296
Name
Twitter
@ArcutisBio
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
ARQT's Discussions on Twitter

Compare ARQT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
13.08 1.53B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-30-24 Initiated H.C. Wainwright Buy
Aug-28-24 Initiated Jefferies Buy
Jan-03-24 Upgrade Mizuho Neutral → Buy
Oct-26-23 Downgrade Mizuho Buy → Neutral
Oct-13-23 Downgrade Goldman Buy → Neutral
Sep-07-22 Initiated Needham Buy
Mar-17-22 Initiated Goldman Buy
Jun-30-21 Initiated Mizuho Buy
May-27-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-09-20 Upgrade Goldman Neutral → Buy
Oct-08-20 Initiated Truist Buy
Feb-25-20 Initiated Cantor Fitzgerald Overweight
Feb-25-20 Initiated Cowen Outperform
Feb-25-20 Initiated Goldman Neutral
Feb-25-20 Initiated Guggenheim Buy
View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

pulisher
Jan 19, 2025

Objective long/short (ARQT) Report - Stock Traders Daily

Jan 19, 2025
pulisher
Jan 18, 2025

Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3% - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4%Time to Sell? - MarketBeat

Jan 18, 2025
pulisher
Jan 16, 2025

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - Yahoo Finance

Jan 16, 2025
pulisher
Jan 14, 2025

Arcutis Biotherapeutics’ (ARQT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Arcutis stock target lifted, buy rating held on significant developments By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap UpStill a Buy? - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Arcutis stock target lifted, buy rating held on significant developments - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews - Benzinga

Jan 13, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Arcutis Shares Climb on Strong Product Revenue Estimates - MarketWatch

Jan 13, 2025
pulisher
Jan 13, 2025

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 13, 2025
pulisher
Jan 13, 2025

Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024 - Marketscreener.com

Jan 13, 2025
pulisher
Jan 12, 2025

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - The Manila Times

Jan 12, 2025
pulisher
Jan 12, 2025

Arcutis Q4 Revenue Surges 366% to $63M as ZORYVE Demand Accelerates Across Indications - StockTitan

Jan 12, 2025
pulisher
Jan 10, 2025

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer -June 01, 2021 at 07:30 am EDT - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Here's What Happened - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Commit To Purchase Arcutis Biotherapeutics At $7.50, Earn 21.3% Using Options - Nasdaq

Jan 10, 2025
pulisher
Jan 09, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says - Defense World

Jan 09, 2025
pulisher
Jan 09, 2025

When the Price of (ARQT) Talks, People Listen - Stock Traders Daily

Jan 09, 2025
pulisher
Jan 07, 2025

Mizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week HighHere's What Happened - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Arcutis stock soars to 52-week high, hits $15.85 amid robust gains - Investing.com

Jan 07, 2025
pulisher
Jan 06, 2025

Mizuho lifts Arcutis stock price target to $20, maintains Outperform By Investing.com - Investing.com Australia

Jan 06, 2025
pulisher
Jan 06, 2025

Arcutis Biotherapeutics director Welgus sells $146,714 in stock By Investing.com - Investing.com Nigeria

Jan 06, 2025
pulisher
Jan 06, 2025

Mizuho lifts Arcutis stock price target to $20, maintains Outperform - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Arcutis Biotherapeutics director Welgus sells $146,714 in stock - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 06, 2025
pulisher
Jan 06, 2025

Arcutis Biotherapeutics Grants 75,500 RSUs to New Hires in Strategic Talent Acquisition Move - StockTitan

Jan 06, 2025
pulisher
Jan 03, 2025

Here's Why Arcutis Stock More Than Doubled In Market Value In One Year - Barchart

Jan 03, 2025
pulisher
Jan 03, 2025

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN

Jan 03, 2025
pulisher
Jan 02, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 7% HigherHere's Why - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - Simply Wall St

Jan 02, 2025
pulisher
Jan 02, 2025

What is HC Wainwright’s Forecast for ARQT FY2024 Earnings? - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

FY2024 Earnings Estimate for ARQT Issued By HC Wainwright - MarketBeat

Jan 01, 2025
pulisher
Jan 01, 2025

Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 By Investing.com - Investing.com Nigeria

Jan 01, 2025
pulisher
Dec 31, 2024

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 1,691 Shares - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 - Investing.com India

Dec 31, 2024
pulisher
Dec 31, 2024

Looking Ahead to 2025 Dermatology Drug Approvals - Dermatology Times

Dec 31, 2024
pulisher
Dec 31, 2024

H.C. Wainwright initiates Buy on Arcutis Biotherapeutics shares highlighting Zoryve potential - Investing.com Canada

Dec 31, 2024
pulisher
Dec 30, 2024

HC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN

Dec 30, 2024

Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Cap:     |  Volume (24h):